Paracetamol With Caffeine to Treat Episodic Tension Type Headache
Launched by GLAXOSMITHKLINE · Dec 19, 2012
Trial Information
Current as of July 21, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Diagnosis of episodic tension-type headache consistent with all of the following:
- • 1. number of days with the condition is historically greater than or equal to two per month
- • 2. onset of condition was greater than or equal to 12 months from Visit 1
- • 3. age of onset was \< 50 years
- • 4. severity of headaches is historically at least moderate
- • 5. duration of headaches is historically greater than or equal to four hours, if untreated
- • 6. number of headache episodes was greater than or equal to 4 and less than or equal to 10 during each of the three months immediately prior to Visit 1
- • 7. treatment of headache episodes with OTC analgesics has historically provided pain relief in less than or equal to 2 hours
- Exclusion Criteria:
- • Subject has chronic tension type headache, which is defined as headache on more than 15 days per month for 3 months.
- • If a migraine sufferer,subject averages more than one episode per month, is incapable of differentiating between tension-type headaches and migraine headaches, and/or requires regular or prophylactic use of migraine medications
About Glaxosmithkline
GlaxoSmithKline (GSK) is a global healthcare company dedicated to improving the quality of human life by enabling people to do more, feel better, and live longer. With a strong focus on research and development, GSK specializes in pharmaceuticals, vaccines, and consumer health products. The company is committed to advancing innovative therapies and preventive measures across various therapeutic areas, including respiratory, oncology, immunology, and infectious diseases. GSK's collaborative approach and rigorous clinical trial processes underscore its dedication to delivering safe and effective healthcare solutions that meet the needs of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Mount Vernon, New York, United States
Pembroke Pines, Florida, United States
Springfield, Massachusetts, United States
Wellesley Hills, Massachusetts, United States
Lake Success, New York, United States
Port Chester, New York, United States
Patients applied
Trial Officials
GSK Clinical Trials
Study Director
GlaxoSmithKline
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials